Safety and Efficacy of Acute Normovolemic Hemodilution in Pediatric Cardiac Surgery Patients
The Efficacy and Safety of Acute Normovolemic Hemodilution in Pediatric Cardiac Surgery Patients
1 other identifier
interventional
24
1 country
1
Brief Summary
The investigators primary objective is to determine if acute normovolemic hemodilution (ANH) for pediatric cardiac surgical patients decreases the volume of blood products transfused during surgery and the immediate post-operative period as compared to usual care. This study will enroll 24 pediatric heart surgery patients, aged 6 months to 3 years old undergoing either ANH prior to initiating cardiopulmonary bypass or the standard of care procedures for the use of cardiopulmonary bypass.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2016
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 13, 2016
CompletedFirst Posted
Study publicly available on registry
April 26, 2016
CompletedStudy Start
First participant enrolled
June 30, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2020
CompletedMay 16, 2019
May 1, 2019
3.5 years
April 13, 2016
May 14, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Effectiveness of ANH to decrease volume of blood products during surgery and the immediate post-operative period.
This will be measured by comparing the volume (mL/Kg body weight) of any blood products administered peri-operatively between the two groups.
2 Days
Secondary Outcomes (8)
Kidney function
2 days
Normalization of thromboelastogrpahy (TEG) MA value (maximum amplitude)
2 days
Normalization of thromboelastography (TEG) R value (reaction time)
2 days
Normalization of thromboelastography (TEG) Alpha Angle value
2 days
Final hematocrit, platelet count, PT/PTT on ICU admission
1 day
- +3 more secondary outcomes
Study Arms (2)
Standard of Care Control
NO INTERVENTIONThis group will consist of all the participants that receive the standard of care treatment for elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
Acute Normovolemic Hemodilution
EXPERIMENTALThis group will consist of all the participants that receive the acute normovolemic hemodilution prior to their elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
Interventions
ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
Eligibility Criteria
You may qualify if:
- Informed signed consent must be obtained by a legally authorized representative.
- Must be undergoing an elective surgical repair or palliation of a cardiac defect with the use of the cardiopulmonary bypass machine.
- Must be clinically stable at the time of evaluation for eligibility and on the day of randomization.
You may not qualify if:
- Patients who carry a diagnosis of a bleeding disorder.
- Patients who have an abnormal coagulation profile as evidenced by a preoperative coagulation screen.
- Patients who have received a blood transfusion in the preceding 120 days.
- Patients who have a diagnosis of a chromosomal abnormality.
- Patients whose participation in the study is deemed unsafe by their primary care team.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Oregon Health and Science Universitylead
- The Gerber Foundationcollaborator
Study Sites (1)
Oregon Health and Science University
Portland, Oregon, 97239, United States
Study Officials
- STUDY DIRECTOR
Miriam Treggiari, MD
Oregon Health and Science University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
April 13, 2016
First Posted
April 26, 2016
Study Start
June 30, 2016
Primary Completion
December 31, 2019
Study Completion
May 31, 2020
Last Updated
May 16, 2019
Record last verified: 2019-05
Data Sharing
- IPD Sharing
- Will not share
There are no plans to share the data collected during this study.